Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC

Summary

Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit. The purpose of this trail is to establish whether advanced non-squamous NSCLC patients could benefit from the combination treatment of docetaxel, carboplatin and anlotinib as the first-line and maintenance treatment.

Timeline

Start

2019-03-01

Primary completion

2019-12-01

Completion

2020-12-01

Drugs

Indications